Intravenous Hydrogen Therapy With Intracisternal Magnesium Sulfate Infusion in Severe Aneurysmal Subarachnoid Hemorrhage

The publication “Intravenous Hydrogen Therapy With Intracisternal Magnesium Sulfate Infusion in Severe Aneurysmal Subarachnoid Hemorrhage” is organized in H2HUBB under the research focus injected hydrogen stroke brain study 2021. The publication is cited as Takeuchi Satoru, Kumagai Kosuke, Toyooka Terushige, Otani Naoki, Wada Kojiro, Mori Kentaro, Stroke, 2021. This randomized controlled trial examined Intravenous Hydrogen Therapy With Intracisternal Magnesium Sulfate Infusion in Severe Aneurysmal Subarachnoid Hemorrhage. The abstract describes Human participants; hydrogen delivered as injected or infused hydrogen; reported duration 14 days. The abstract reports: Intracisternal magnesium sulfate infusion started immediately after surgery reduces the incidence of cerebral vasospasm and delayed cerebral ischemia and improves clinical outcomes without complications…. This is an automated editorial draft based on the abstract and requires source review before publication.

Injected hydrogen stroke brain study 2021 overview

Poor-grade subarachnoid hemorrhage still has a poor prognosis. This randomized controlled clinical trial evaluated intracisternal magnesium sulfate infusion combined with intravenous hydrogen therapy in… Because this is human clinical evidence, relevance depends on participant selection, controls, sample size, treatment duration, adherence, outcome measures, and replication.

Study design and hydrogen intervention

Publication type: Randomized controlled trial. Evidence type: Human clinical evidence. Research model or population: Human participants. Randomized: Yes. Blinding: Double-blind. Control status: Control group reported.

Delivery method: Injected or infused hydrogen. Hydrogen concentration: 2.5 mmol/L. Dose or treatment amount: 20 mL. Treatment duration: 14 days.

Reported findings and scientific interpretation

For this injected hydrogen stroke brain study 2021, the study record reports the following: The abstract reports: Intracisternal magnesium sulfate infusion started immediately after surgery reduces the incidence of cerebral vasospasm and delayed cerebral ischemia and improves clinical outcomes without complications…

These findings should be interpreted as one piece of evidence rather than as a stand-alone medical conclusion. Results can be influenced by the research model, study design, treatment protocol, sample size, outcome selection, statistical methods, and whether the findings have been independently reproduced.

How this research record was prepared

H2HUBB organizes bibliographic details, study design information, intervention data, outcomes, limitations, and safety notes from the available scientific source. Automated classification supports database organization, but it does not replace critical reading of the complete paper. Source identifiers, evidence labels, and delivery-method fields are retained so readers can verify the record and compare it with related publications. A missing field means the information was unavailable or not reported in the structured source; it should not be treated as a negative finding.

Limitations, safety, and original source

Limitations: The intervention or follow-up period appears relatively short.

Safety: The abstract did not provide detailed safety or adverse-event information.

This H2HUBB page is an educational research record, not medical advice. Review the original scientific source for the complete methods and results. Continue exploring the H2HUBB Molecular Hydrogen Research Library to compare evidence types, delivery methods, and related topics.